We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
+3.67%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$450M
AUM Growth
-$279M
Cap. Flow
-$152M
Cap. Flow %
-33.77%
Top 10 Hldgs %
60.29%
Holding
78
New
9
Increased
12
Reduced
27
Closed
29

Top Buys

Rank Stock Value
1
AMRN
Amarin Corp
AMRN
+$35.2M
2
TEVA icon
Teva Pharmaceuticals
TEVA
+$25.3M
3
OSUR icon
OraSure Technologies
OSUR
+$12.9M
4
CTLT
CATALENT, INC.
CTLT
+$11.9M
5
AMRX icon
Amneal Pharmaceuticals
AMRX
+$7.57M

Top Sells

Rank Stock Value
1
TGTX icon
TG Therapeutics
TGTX
+$34M
2
AZN icon
AstraZeneca
AZN
+$27.9M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$23.9M
4
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$15.9M
5
MYOV
Myovant Sciences Ltd.
MYOV
+$15.7M

Sector Composition

Rank Sector Weight
1 Healthcare 97.16%
2 Communication Services 1.48%
3 Miscellaneous 1.32%
4 Financials 0.04%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ITCI
26
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$4.54M 1.01%
+176,758
New +$4.03M
AFMD
27
DELISTED
Affimed
AFMD
$4.22M 0.94%
124,546
+30,247
+32% +$1.15M
BCRX icon
28
BioCryst Pharmaceuticals
BCRX
$2.51B
$3.93M 0.87%
1,143,211
-3,704,581
-76% -$15.9M
OXFD
29
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$3.43M 0.76%
293,277
-56,861
-16% -$755K
AZN icon
30
AstraZeneca
AZN
$252B
$3.34M 0.74%
30,468
-250,608
-89% -$27.9M
MRSN
31
DELISTED
Mersana Therapeutics
MRSN
$2.61M 0.58%
+5,600
New +$2.83M
SNY icon
32
Sanofi
SNY
$107B
$2.5M 0.55%
49,778
– –
GSK icon
33
GSK
GSK
$102B
$2.45M 0.55%
51,498
-130,312
-72% -$6.53M
APLS
34
DELISTED
Apellis Pharmaceuticals
APLS
$2.45M 0.54%
81,267
-339,665
-81% -$10.1M
CLDX icon
35
Celldex Therapeutics
CLDX
$3.07B
$2.23M 0.5%
150,494
-562,204
-79% -$6.59M
CARM
36
DELISTED
Carisma Therapeutics
CARM
$2.18M 0.49%
77,991
-22,009
-22% -$440K
QDEL icon
37
QuidelOrtho
QDEL
$1.01B
$2.05M 0.46%
+9,343
New +$2.08M
PRTA icon
38
Prothena Corp
PRTA
$479M
$1.97M 0.44%
197,028
+44,815
+29% +$539K
OTIC
39
DELISTED
Otonomy, Inc.
OTIC
$1.67M 0.37%
412,500
-188,663
-31% -$711K
KALV
40
DELISTED
KalVista Pharmaceuticals
KALV
$1.35M 0.3%
107,300
+17,494
+19% +$219K
CNCE
41
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$1.02M 0.23%
103,829
-129,154
-55% -$1.27M
LQDA icon
42
Liquidia Corp
LQDA
$6.06B
$899K 0.2%
182,751
-676,973
-79% -$3.92M
LCI
43
CALL
DELISTED
Lannett Company, Inc.
LCI
$636K 0.14%
+30,625
New +$726K
SLDB icon
44
Solid Biosciences
SLDB
$1.05B
$623K 0.14%
20,468
-6,667
-25% -$255K
TARA icon
45
Protara Therapeutics
TARA
$226M
$611K 0.14%
36,310
-10,000
-22% -$232K
SCPH
46
DELISTED
scPharmaceuticals
SCPH
$489K 0.11%
65,605
-181,814
-73% -$1.42M
SRPT icon
47
Sarepta Therapeutics
SRPT
$2.2B
$266K 0.06%
1,897
-69,834
-97% -$10.6M
TLGT
48
DELISTED
Teligent, Inc
TLGT
$220K 0.05%
305,423
-49,575
-14% -$87.2K
GOCO
49
DELISTED
GoHealth
GOCO
$171K 0.04%
+875
New +$211K
AL
50
PUT
DELISTED
Air Lease Corp
AL
– –
-20,000
Closed -$586K
1
2
3 4

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q3 2020 Portfolio in Review

As of Q3 2020, Eversept Partners held 78 positions worth $450M, down 38% from $729M the previous quarter. Its ten largest holdings account for 60% of the portfolio.

Eversept Partners withdrew a net $152M in Q3 2020, closing 29 positions and reducing 27 holdings. Its most notable exit was Myovant Sciences Ltd., an estimated $15.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 81% a quarter earlier, followed by Communication Services and Miscellaneous.

Against the trend, Eversept Partners opened a new position in Teva Pharmaceuticals worth $21.6M.

  • Eversept Partners's largest Q3 2020 buy was Teva Pharmaceuticals: 2,394,355 shares worth $21.6M.
  • Eversept Partners added most to Amarin Corp in Q3 2020, an estimated $35.2M increase.
  • Eversept Partners's biggest Q3 2020 reduction was TG Therapeutics, cutting an estimated $34M.
  • Eversept Partners fully exited Myovant Sciences Ltd. in Q3 2020, selling an estimated $15.7M.
  • Eversept Partners's ten largest holdings make up 60% of its $450M portfolio in Q3 2020.
  • Eversept Partners opened 9 new positions and closed 29 in Q3 2020.
  • Eversept Partners's portfolio value fell 38% quarter-over-quarter to $450M.

Based on Eversept Partners's 13F filing for Q3 2020, filed 12 Nov 2020.